Arti-Cell Forte

RSS

chondrogenic induced equine allogeneic peripheral blood-derived mesenchymal stem cells

Authorised
This medicine is authorised for use in the European Union.

Overview

Arti-Cell Forte is a veterinary medicine used to treat mild to moderate lameness linked to non-infective joint inflammation in horses. It contains stem cells which are obtained from equine blood. Stem cells can develop into other types of cells. The stem cells in the active substance (mesenchymal stem cells) are treated so that they develop into cartilage cells.

This EPAR was last updated on 07/05/2019

Authorisation details

Product details
Name
Arti-Cell Forte
Agency product number
EMEA/V/C/004727
Active substance
chondrogenic induced equine allogeneic peripheral blood-derived mesenchymal stem cells
International non-proprietary name (INN) or common name
chondrogenic induced equine allogeneic peripheral blood-derived mesenchymal stem cells
Species
Horses
Publication details
Marketing-authorisation holder
Global Stem cell Technology
Revision
0
Date of issue of marketing authorisation valid throughout the European Union
29/03/2019
Contact address
Noorwegenstraat 4
9940 Evergem
Belgium

Product information

22/06/2018 Arti-Cell Forte - EMEA/V/C/004727 -

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Not yet assigned

Therapeutic indication

Reduction of mild to moderate recurrent lameness associated with non-septic joint inflammation in horses.

Assessment history

How useful was this page?

Add your rating
Average
3 ratings